About
Our Story
Our People
Our Advisors
Science
Pipeline
Izokibep
Lonigutamab
SLRN-517
Presentations & Publications
Community
Patients
Partnerships
Investors & Media
Overview
Press Releases
Events & Presentations
Financials & Filings
Corporate Governance
Email Alerts
Investor Resources
Media Resources
Careers
Stories
Contact Us
Presentation
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 16 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2b/3 Study
June 15, 2024
Share
Download Presentation
Copy